PARP Inhibitor Market is estimated to be US$ 41435.5 million by 2030 with a CAGR of 34.3% during the forecast period

PARP Inhibitor Market accounted for US$ 2178 million in 2020 and is estimated to be US$ 41435.5 million by 2030 and is anticipated to register a CAGR of 34.3%. PARP inhibitors are poly ADP ribose polymerase and are developed for multiple indications including treatment of heritable cancers. Several forms are dependent on PARP rather than regular cells, making PARP an attractive target for cancer therapy. They are considered as potential treatment for acute life threatening disease such as stroke and myocardial infarction.

The report " Global PARP Inhibitor Market, By Drug (Lynparza, Niraparib, Rucaparib and Others), By Indication (Ovarian cancer, Breast cancer, Prostate cancer, Lung cancer and Others), By Distribution Channel (Hospital pharmacies, Online pharmacies and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Trends, Analysis, and Forecast till 2030”

Key Highlights:

In April 2020, GSK expanded its market for cancer therapy Zejula by acquiring Tesaro in US $5 billion and winning FDA approval for the drug in patients for ovarian cancer.
In July 2019, UT Southwestern Medical Center’s new research covering a mechanism by which drugs attack cancer and suggested that they can be put in many more patients.
Analyst View:

Increasing incidence of cancers is the major growth driver of global PARP inhibitor market. For ovarian cancer treatments there is high demand of PARP inhibitors which drives the market. Various organizations such as WHO, FEAT, and others along with the government are spreading awareness about this condition which is anticipated to facilitate market growth in the forecast period.

Before purchasing this report, request a sample or make an inquiry by clicking the following link:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4668

Key Market Insights from the report:

The Global PARP Inhibitor Market accounted for US$ 2178 million in 2020 and is estimated to be US$ 41435.5 million by 2030 and is anticipated to register a CAGR of 34.3%. The Global PARP Inhibitor Market is segmented based on the drug, indication, distribution channel and region.

On the basis of drug, the global PARP inhibitor market is segmented into Lynparza, niraparib, rucaparib and others.
Based on indication, the target market is segmented into ovarian cancer, breast cancer, prostate cancer, lung cancer and others.
On the basis of distribution channel, the target market is segmented into hospital pharmacies, online pharmacies and others.
By region, the Global PARP Inhibitor Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the worldwide leader in the PARP inhibitor market in terms of revenue, due to the developed healthcare system and health awareness among people.
Competitive Landscape:

The key players operating in the global PARP inhibitor market includes AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Jiangsu Hengrui Medicine Co., Ltd, Clovis Oncology Inc., AbbVie Inc., Bristol – Myers Squibb, Merck KGaA, Genentech, Inc.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.